Chemistry:Soclenicant
Soclenicant (INN),[1] also known by its developmental code names BNC210 and IW-2143 and as L-isoleucyl-L-tryptophan, is an antinicotinic agent which is under development for the treatment of anxiety disorders such as social phobia and generalized anxiety disorder, as well as for treatment of agitation, post-traumatic stress disorder (PTSD), and depressive disorders.[2][3][4] It is taken by mouth.[3]
The drug acts as a highly selective negative allosteric modulator (NAM) of the α7-nicotinic acetylcholine receptor (α7-nAChR).[2][5][3][4] It produces anxiolytic-, anti-stress-, and antidepressant-like effects without causing sedation, memory or motor impairment, or physical dependence in rodents.[5] Chemically, soclenicant is a dipeptide of the amino acids L-tryptophan and L-isoleucine and can be considered a tryptamine derivative.[6]
Soclenicant is being developed by Bionomics.[3] It has also been developed by Ironwood Pharmaceuticals and EmpathBio.[3][4] Bionomics was acquired by Neuphoria Therapeutics in December 2024.[3] As of December 2024, soclenicant is in phase 3 clinical trials for anxiety disorders, phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders.[3][4] The drug received Fast Track designation from the United States Food and Drug Administration (FDA) in 2019.[7] It was first described in the literature, in a conference abstract, by 2007.[8]
See also
- List of investigational anxiolytics
- List of investigational social anxiety disorder drugs
- 5-Hydroxyindoleacetic acid
- Desformylflustrabromine
- Kynurenic acid
References
- ↑ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf#page=198 soclenicantum soclenicant 6-[(2,3-dihydro-1H-inden-2-yl)amino]-1-ethyl-3-(morpholine4-carbonyl)-1,8-naphthyridin-4(1H)-one nicotinic acetylcholine receptor negative allosteric modulator, anxiolytic
- ↑ 2.0 2.1 "BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders". Expert Opin Investig Drugs 32 (4): 277–282. April 2023. doi:10.1080/13543784.2023.2192922. PMID 36927202.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "BNC 210". 30 December 2024. https://adisinsight.springer.com/drugs/800030421.
- ↑ 4.0 4.1 4.2 4.3 "Delving into the Latest Updates on BNC-210 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/ca1840632fb24a8291a57242a61661af.
- ↑ 5.0 5.1 "BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents". Neuropharmacology 246. March 2024. doi:10.1016/j.neuropharm.2024.109836. PMID 38185416.
- ↑ "CID 7019084". https://pubchem.ncbi.nlm.nih.gov/compound/7019084.
- ↑ Bionomics Limited Press Release (2019-11-04). "Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD". BusinessWire. https://www.businesswire.com/news/home/20191104005291/en/Bionomics-Announces-Fast-Track-Designation-Granted-U.S..
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedAndriambelosonWagnerHuyard2007
 |  |
